STHLM3RS


Martin Steinberg
Project Leader
Karolinska Institutet

Per Matsson
CTO
Thermo Fisher Scientific

Individual Prostate Cancer Risk Score

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data and a multivariate algorithm to create a more accurate way to screen for the risk of prostate cancer. STHLM3RS aims at accelerating introduction of Stockholm3 in Europe. Activities include clinical validation and development of a “technology agnostic” version that works on many platforms.

Origins

Currently, the most widely used blood test for prostate cancer is controversial because it can give false positives that lead men to have unneeded treatments or invasive tests that cause new health problems. Stockholm3 identifies twice as many aggressive prostate cancers and reduces the risk of conducting unnecessary prostate biopsies by 50%.

Team

STHLM3RS is led by Karolinska Institutet, a world-leading medical university, and Thermo Fisher Scientific, which provides both deep scientific knowledge and industrial and business development experience. Validation partners for STHLM3RS include clinicians at Erasmus University, University Medical Center Groningen, Friedrich-Alexander-Universität Erlangen and Taunton and Somerset NHS Foundation Trust.

The project

The EIT Health STHLM3RS Innovation Project aims at accelerating the introduction of Stockholm3 in Europe.

Key activities carried out during the project include:

  • Clinical validation at five hospitals in Germany, Holland and the UK.
  • Implementation of a technology agnostic solution.
  • Setting up of a demonstration hospital at Capio S:t Göran Prostate Cancer Center in Stockholm, Sweden.
  • Development of second-generation technology to analyse Stockholm3.
  • Two spin-out companies:
    • OncoAlgorithm: Develops/market tools that use genomics, proteomics and imaging in modern medicine.
    • A23Lab: Sells a Research use Only (RUO) version of Stockholm3 as a Lab Developed test (LDT) in the Swedish/Nordic markets and acts as reference lab for further European roll-out.

Impact

Benefits of Stockholm3 include lower mortality from prostate cancer and fewer harmful misdiagnoses. Health economic calculations have proven the value of Stockholm3 for society. The STHLM3RS project has already achieved much in accelerating use of Stockholm3:

  • Stockholm3 has been validated in several key markets.
  • Stockholm3 has been implemented in clinical care as an LDT in Sweden, Norway and Finland.
  • Stockholm3 has received strong interest from major lab chains in Europe and elsewhere.

Why this is an EIT Health project

This project drives a key goal of EIT Health by helping to accelerate a proven healthcare innovation toward the market. The project is particularly in keeping with the EIT Health Focus Area of “Care Pathways”, because it promises improved diagnoses of a potentially deadly condition that can better be treated if it is detected early.

See the STHLM3RS Success Story.

EIT Health partners in this project